Stock DMAC DIAMEDICA THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages DiaMedica Therapeutics Inc.

Equities

DMAC

CA25253X2077

Market Closed - Nasdaq
Other stock markets
 21:00:00 24/06/2024 BST 		5-day change 1st Jan Change
2.22 USD +2.78% Intraday chart for DiaMedica Therapeutics Inc. -7.11% -21.83%
05-23 DiaMedica Therapeutics Inc. Elects Rick Pauls as Director CI
05-09 Transcript : DiaMedica Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
DiaMedica Therapeutics Inc. Elects Rick Pauls as Director
DiaMedica Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
DiaMedica Therapeutics Inc. Announces Executive Changes
DiaMedica Therapeutics Files $100 Million Mixed Shelf
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer
DiaMedica Therapeutics Inc. Appoints Dr. Lorianne Masuoka as Chief Medical Officer
DiaMedica Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Top Premarket Gainers
DiaMedica Therapeutics Inc. Announces the Appointment of Ambarish Shah as Chief Technology Officer
Diamedica Therapeutics Inc. Announces Management Changes
DiaMedica Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Insider Buy: Diamedica Therapeutics
Insider Buy: Diamedica Therapeutics
Insider Buy: Diamedica Therapeutics
DiaMedica Therapeutics Announces US FDA's Removal of Clinical Hold on Phase 2/3 Trial for Ischemic Stroke Treatment DM199
DiaMedica Therapeutics Inc. Announces That the FDA Has Removed the Clinical Hold on Dm199 Phase 2/3 Trial Forschemic Stroke
Diamedica Therapeutics Announces Appointment of Richard Kuntz to the Board of Directors
Diamedica Therapeutics Inc. Files Complete Clinical Hold Response with the U.S. Food and Drug Administration Regarding the Status of the Remedy2 Study
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DMAC Stock
  4. News DiaMedica Therapeutics Inc.
  5. Other languages